3D Bioprinting Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global 3D bioprinting market growth forecasted to transform from USD 1.3 billion in 2024 to USD 2.4 billion by 2029, driven by a CAGR of 12.7%. The market growth is fueled by growing adoption of 3D bioprinting technology in the pharmaceutical and cosmetic industries, technological advancement in the 3D bioprinting and rising demand for organ transplants.

3D bioprinting Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Global 3D bioprinting market Dynamics

Driver: Growing adoption of 3D bioprinting technology within the pharmaceutical and cosmetic industries

Increasing adoption of 3D bioprinting technology in the pharmaceutical industry has catalyzed substantial growth in the market. This innovative technology enables the precise fabrication of tissues and organs, offering pharmaceutical & biotechnology companies unprecedented opportunities for drug testing, disease modeling, and personalized medicine development. By accurately replicating the complex structures of human tissues, 3D bioprinting allows for more reliable preclinical testing, reducing the need for animal models and accelerating the drug development process. Moreover, it helps create patient-specific organ models for studying diseases and developing tailored treatments, thereby fostering advancements in precision medicine. cosmetology industry, companies leverage bioprinted skin tissue models to conduct more precise evaluations of the safety and efficacy of skincare products. These models replicate the structure and function of human skin, providing an authentic platform to evaluate how products interact with skin cells, tissues, and microbiota. By utilizing bioprinted skin models, companies can streamline product development processes, reduce reliance on animal testing, and ensure that their products adhere to rigorous safety standards while delivering optimal results for consumers. For instance, in June 2023, BICO Group AB (Sweden) Group, which includes CELLINK, Dispendix, ABM, and Sartorius (Germany), entered into a sub-sales and distribution agreement under which Sartorius distributed a range of instruments such as CELLINK’s 3D bioprinting portfolio: BIO X, BIO X6 and BIONOVA X, Dispendix’ liquid handling platform I.DOT MINI, and a wide range of bioinks and reagents from Advanced BioMatrix ( ABM) to their customers in the Asia Pacific.

Restraint: High cost of 3D bioprinters and bioinks

The high cost of 3D bioprinting poses a significant challenge to its widespread adoption and accessibility. This cutting-edge technology, which holds immense promise in revolutionizing healthcare and regenerative medicine, requires sophisticated equipment, specialized materials, and skilled expertise, all of which contribute to its hefty price tag. For example, 3D bioprinters are highly precise machines that use complex designs and advanced systems to accurately place biological materials layer by layer. These printers can cost hundreds of thousands to millions of dollars because of their sophisticated design. Creating the bioinks used in printing, which contain living cells and special materials, requires a lot of research and special processes to make sure they are efficient and safe for the human body

Opportunity: Rising demand for organ transplants

As chronic conditions, such as diabetes, hypertension, and kidney disease, have become more prevalent worldwide, the number of patients requiring organ transplantation continues to rise. These chronic diseases can lead to organ failure or irreversible damage, necessitating life-saving transplant procedures to improve patient outcomes and quality of life. For instance, as of March 2024, there are currently over 103,000 people on the national transplant waiting list and every 8 minutes, another person is added to the list; over 17 people die every year waiting for organ transplants. Similarly, as per the data released by the United Network for Organ Sharing, the number of transplants performed in the US has increased annually, with more than 46,000 organ transplants performed in 2023. Likewise, the number of registrants for organ donation reached 6.7 million in 2023 from 1,087 in 2010 in China

Challenge: Biocompatibility issues and rigorous sterilization protocols

Ensuring biocompatibility is a paramount concern in the field of 3D bioprinting, crucial for seamlessly integrating constructs into living tissues while mitigating potential adverse reactions. This begins with careful material selection, favoring natural polymers and synthetic compounds, which emulate tissue properties while minimizing immunogenicity and toxicity risks. The formulation of bioinks, containing cells within a hydrogel matrix, is pivotal for supporting optimal cell viability, proliferation, and differentiation throughout the printing process.

Biocompatibility issues can also result in organ rejection if the transplanted organ is incompatible with the recipient's body. This occurs when the recipient's immune system identifies the transplanted tissue as foreign and triggers an immune response against it, targeting specific surface proteins known as antigens. Consequently, antibodies are produced, and immune cells are activated to attack and damage the transplanted tissue. This rejection process can occur acutely, shortly after transplantation, or chronically over an extended period. According to the National University Centre for Organ Transplantation at the National University Hospital (NUH), between 30 to 40% of kidney transplants are lost over time to rejection. Addressing biocompatibility concerns is crucial in transplantation to mitigate the risk of rejection and ensure the long-term success of the transplant

3D bioprinting Market Ecosystem

The 3D bioprinter segment is projected to hold the 3D bioprinting industry dominant position during the forecast period.

Based on component, the 3D bioprinting market is divided into various segments: 3D bioinks, bioprinters, software, and consumables. The 3D bioprinters is segmented into, inkjet 3D bioprinters, laser-assisted bioprinters, magnetic 3D bioprinters, Microextrusion bioprinters, stereolithography-based bioprinters, and other 3D bioprinters (microvalve bioprinters and tissue fragment bioprinters). The bioin segment is also subdidvided into synthetic, natural and hyrdid bioinks. The 3D bioprinters segment anticipated to account highest share in the market in 2023. lucrative demand for organ transplants coupled with innovation in 3D bioprinting technology serves as driving factor in the market.

North America was the largest regional market for 3D bioprinting industry for both (excluding & including COVID -19 3D bioprinting) in 2023.

The market is segmented into five major regions namely, North America, Europe, the Asia Pacific, Latin America, Middle East and Africa. In 2023, North America accounted for the largest share of the 3D bioprinting market and expected to retain dominance throughout the forecast period of 2024-2029. Favorable regulatory policies, reimbursement scenario, presence of key market players in the region are some of the major factors uplifting the market growth in the North America. Europe is likely to grow at significant CAGR owing to various factors such as advancements in bioprinting research and development, increasing healthcare expenditure and government initiatives aimed at expanding 3D bioprinting.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the market include BICO Group AB (Sweden), 3D Systems Inc. (US), Merck KGaA (Germany), Organovo Holdings Inc (US), Collplant Biotechnologies Ltd. (Israel), regenHU (Switzerland), Aspect Biosystem Ltd. (Canada), Advanced Solutions Life Sciences, LLC (US), Cyfuse Biomedical K.K (Japan), Rokit Healthcare Inc. (South Korea), Hangzhou Genofei Biotechnology Co., Ltd. (China), Foldink (Armenia), Brinter (US), 3D bioprinting solution (Russia), REGEMAT 3D, SL (Spain), Ροietis (France), Sunp Biotech (US), GeSim – Gesellschaft Für Silizium-Mikrosysteme Mbh (Germany), Medprin (China), Voxcell Bioinnovation Inc. (Canada), Prodways (France), Inventia Life Science Pty Ltd (Australia), Upnano Gmbh (Austria), UPM (Finland), and Tissuelabs (Switzerland)

3D Bioprinting Market Report Scope

This report categorizes the 3D bioprinting market to forecast revenue and analyze trends in each of the following submarkets:

By Component

• 3D Bioprinters
  • Microextrusion Bioprinters
  • Inkjet 3D Bioprinters
  • Laser-Assisted Bioprinters
  • Stereolithography-Based Bioprinters
  • Magnetic 3D Bioprinters
  • Other 3D Bioprinters
• Bioinks
  • Natural Bioinks
  • Hybrid Bioinks
  • Synthetic Bioinks
• Software
• Consumables

By Material

• Living Cells
• Hydrogels
• Extracellular Matrices
• Other Materials

By Application

• Research Application
  • Drug Research
  • Regenerative Medicine
  • 3D Cell Culture
• Clinical Applications
  • Skin
  • Bone and Cartilage
  • Blood Vessels
  • Other Clinical Applications

By End User

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (ROE)
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • RoLATAM
• Middle East
  • GCC
    • Saudi Arabia (KSA)
    • United Arab Emirates (UAE)
    • Rest of GCC
  • Rest of Middle East
• Africa

Recent Developments of 3D Bioprinting Market

• In February 2024, BICO Group AB (Cellink) launched DNA Studio 4 Vault, a bioprinting software, providing users with confidence and trust in their documentation, enabling a faster translation from the research lab to the clinic
• In February 2024, Merck KGaA (Germany) established a distribution center in Brazil with an investment of USD 21.7 million to better serve its Life Science customers for faster deliveries in the region.
• In April 2023, Aspect Biosystem Ltd (Canada) and Novo Nordisk (Denmark) entered into a collaboration, development, and Licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body to deliver a new class of truly disease-modifying treatments for diabetes and obesity.
• In April 2023, CollPlant Biotechnologies Ltd (Israel) and Stratasys (US) entered into a collaboration for the development of collaborated to develop a solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst